Melissa Dawn Miller, PTA | |
2807 Weatherstone Dr, Kirksville, MO 63501-5654 | |
(660) 216-9531 | |
Not Available |
Full Name | Melissa Dawn Miller |
---|---|
Gender | Female |
Speciality | Physical Medicine & Rehabilitation |
Location | 2807 Weatherstone Dr, Kirksville, Missouri |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1659038354 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208100000X | Physical Medicine & Rehabilitation | 2002003120 (Missouri) | Primary |
Mailing Address | Practice Location Address |
---|---|
Melissa Dawn Miller, PTA 2807 Weatherstone Dr, Kirksville, MO 63501-5654 Ph: (660) 216-9531 | Melissa Dawn Miller, PTA 2807 Weatherstone Dr, Kirksville, MO 63501-5654 Ph: (660) 216-9531 |
News Archive
The rate of myocardium glucose utilisation in the right ventricle correlates with its function and could be used to monitor treatment effects in patients with pulmonary arterial hypertension, findings indicate.
Researchers in Singapore and UK as part of the EpiGen consortium worked together with scientists at the Nestlé Research Center, Switzerland, on a new study on the bacterial makeup of the gut (gut microbiota) of infants in Singapore. Their study reveals that the rate of bacterial colonisation of the gut is influenced by external factors such as the method of delivery and duration of gestation.
Fifteen percent to 20 percent of people worldwide suffer from migraines - excruciating headaches often presaged by dramatic sensations, or "auras." By studying a rare, inherited form of migraine, researchers at Vanderbilt University Medical Center have found clues to the biological basis of the painful, debilitating disorder.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major player in RNAi industry to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.
› Verified 2 days ago